Table 1 Age at treatment initiation and short-term GH treatment outcomes in children born SGA

Argente 2007 [46]

39^b

MC, C, R, O/2 years

2 to <4 years

1.7 at 1 year; approximately 2.5 at 2 years

<0.05

4 to 5 years

1.2 at 1 year; approximately 1.8 at 2 years

Carvalho-Furtado 2009 [47]

39

Ob/1 year

Prepubertal

0.75

=0.016

Pubertal

0.40

Lee 2008 [16]

433

MC, NordiNet IOS/≥1 year

Mean age 6.7 to 9.3

6.7 years = 1.0 and 0.8; 7.6 years = 0.72; 8.3 years = 0.61; 9.3 years = 0.57

<0.0001^c

Ranke 2003 [19]

613 year 1;

KIGS, clinical trials/2 years

Mean age 6.6/statistical models predicting growth response

Year 1: GH dose (35% of variability), age at treatment start (11% of variability)

<0.0001 <0.0001

385 year 2

Year 2: HV in year 1 of treatment (29% of variability), age at treatment start (3% of variability), GH dose (2% of variability)

Ross 2010 [15]

208 year 1;119 year 2

ANSWER Program registry/2 years

Mean age 8.4/males <11 years vs ≥11 years; females <10 years vs ≥10 years

Year 1 boys: <11 years = 0.82; ≥11 years = 0.27Year 1 girls: <10 years = 0.58; ≥10 years = 0.41Year 2 boys: <11 years = 1.23; ≥11 years = 0.59Year 2 girls: <10 years = 1.00; ≥10 years = 0.87

<0.0001 = 0.093 = 0.0005 = 0.56